Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | YAP1 | P46937 | 1/20 | 0.52 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815957 | 0.82 | USP2 (0.78) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL7356750 | 0.82 | USP2 (0.78) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL4892974 | 0.80 | USP2 (0.62) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3339720 | 0.79 | KMT2A (1.00) | RAB9AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL7304896 | 0.78 | KDM4E (0.70) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7304903 | 0.78 | KDM4E (0.70) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5949555 | 0.76 | TSHR (0.61) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL5949547 | 0.76 | TSHR (0.61) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL21800594 | 0.74 | SMN1; SMN2 (0.54) | GAASMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL21800651 | 0.73 | ALDH1A1 (0.71) | NPC1RAB9AKMT2AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | ETERNYGEN GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | ETERNYGEN GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | CS, SLC2A1, SLC2A2 | GAA 108/4885SMN1; SMN2 2915/4885NPC1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.